|
Oct 3
|
Here's My Prescription for Eli Lilly Investors
|
|
Oct 3
|
Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies
|
|
Oct 3
|
Traders Gain 1000% in a Day on Timely Point Biopharma Option Bet
|
|
Oct 3
|
Lilly to Buy Point Biopharma. Cancer-Treatment Stock Surges 84%.
|
|
Oct 3
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Oct 3
|
Point Biopharma stock soars on $1.4B takeover bid from Eli Lilly
|
|
Oct 3
|
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
|
|
Oct 3
|
Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
|
|
Oct 3
|
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
|
|
Oct 3
|
Point Biopharma spikes after Eli Lilly agrees to buy cancer-drug firm for $1.4 bn
|
|
Oct 2
|
SolarEdge, Insulet, and Dollar General Lead S&P 500 Q3 Losses
|
|
Oct 2
|
Eli Lilly Gets FDA Letter About Eczema Drug Concerns
|
|
Oct 2
|
ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day
|
|
Oct 2
|
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
|
|
Oct 2
|
UPDATE 3-U.S. FDA declines to approve Eli Lilly's drug to treat eczema
|
|
Aug 11
|
Pharma ETFs in Focus Post Q2 Earnings
|
|
Aug 11
|
Why Shares of Eli Lilly Jumped This Week
|
|
Aug 11
|
Lilly Endowment Inc. Reduces Stake in Eli Lilly and Co.
|
|
Aug 11
|
Market Rally On The Ropes, AI Stocks Tumble: Weekly Review
|
|
Aug 11
|
Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk
|